Pricing Log in Create free account

Inhibikase Therapeutics, Inc. (IKT) vs Lineage Cell Therapeutics, Inc. (LCTX)

Inhibikase Therapeutics, Inc. and Lineage Cell Therapeutics, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Lineage Cell Therapeutics, Inc. are of similar size ($255.4M and $250.5M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against 19.9%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (0.00% vs −186.8%). Across the 18 metrics below, Inhibikase Therapeutics, Inc. leads on 11 and Lineage Cell Therapeutics, Inc. on 7.

Valuation

Metric IKT LCTX Biotechnology median
P/E n/m n/m 8.50
P/S 1,105.73 18.69 9.71
P/B 1.88 4.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 495.30 14.81 9.21
Earnings yield (26.06%) (14.67%) (33.15%)
Free cash flow yield (14.80%) (9.98%) (25.50%)

Profitability

Metric IKT LCTX Biotechnology median
Gross margin 100.00% 99.46% 65.16%
Operating margin 0.00% (205.23%) 0.00%
Net margin 0.00% (246.58%) 0.00%
Free cash flow margin 0.00% (186.43%) 0.00%
Return on equity (51.96%) (60.35%) (56.36%)
Return on assets (48.04%) (32.75%) (48.04%)
Return on invested capital 0.00% (186.79%) 0.00%

Growth

Metric IKT LCTX Biotechnology median
Revenue growth (TTM) 110.93% 19.87% 6.02%
EPS growth (last fiscal year) 57.76% (211.11%) 30.26%
Revenue growth, 5-year CAGR (42.21%) 51.46% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IKT LCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.82 6.61 4.72
Net debt to EBITDA 3.44 2.64 0.96

Dividend

Metric IKT LCTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IKT LCTX Biotechnology median
Market cap 255.35m 250.45m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack